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Abstract
Background: Cardiac troponins (cTn) are specific markers 
for cardiac damage and acute coronary syndromes. The 
availability of new high-sensitivity assays allows cTn 
detection in healthy people, thus permitting the estima-
tion of biological variation (BV) of cTn. The knowledge 
of BV is important to define analytical performance 
specifications (APS) and reference change values (RCVs). 
The aim of this study was to estimate the within- and 
between-subject weekly BV (CVI, CVG) of cTnI applying 
two high-sensitivity cTnI assays, using European Biologi-
cal Variation Study (EuBIVAS) specimens.
Methods: Thirty-eight men and 53  women underwent 
weekly fasting blood drawings for 10 consecutive weeks. 
Duplicate measurements were performed with Singulex 
Clarity (Singulex, USA) and Siemens Atellica (Siemens 
Healthineers, Germany).
Results: cTnI was measurable in 99.4% and 74.3% of the 
samples with Singulex and Atellica assays, respectively. 
Concentrations were significantly higher in men than in 
women with both methods. The CVI estimates with 95% 
confidence interval (CI) were for Singulex 16.6% (15.6–17.7) 
and for Atellica 13.8% (12.7–15.0), with the observed dif-
ference likely being caused by the different number of 
measurable samples. No significant CVI differences were 
observed between men and women. The CVG estimates for 
women were 40.3% and 36.3%, and for men 65.3% and 
36.5% for Singulex and Atellica, respectively. The result-
ing APS and RCVs were similar for the two methods.
Conclusions: This is the first study able to estimate cTnI 
BV for such a large cohort of well-characterized healthy 
individuals deriving objective APS and RCV values for 
detecting significant variations in cTnI serial measure-
ments, even within the 99th percentile.
Keywords: analytical performance specifications; biologi-
cal variation; high-sensitivity cardiac troponin I;  reference 
change value.
Introduction
Cardiac troponin (cTn) assays are the mainstay for the 
diagnosis of acute myocardial infarction (AMI) [1–3] as 
well as markers of cardiac damage [4, 5] and prognos-
tic indicators of all-cause mortality [6]. It is critical to 
 understand if the observed variations in cTn concentra-
tion are really associated with a pathological condition or 
may just be attributable to analytical and biological varia-
tion (BV). The availability of new high-sensitive [7] or even 
 “ultra-sensitive” [8, 9] methods allows for measurement of 
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cTnI in the majority of healthy subjects, allowing for the 
use of cTn as a risk indicator in the general population, for 
which there is increasing evidence [4, 6, 10]. This enhances 
the need for relevant and robust estimates of BV also in 
a long-term setting in healthy individuals to aid in the 
interpretation of changes in cTn, as well as establishing 
reference change value (RCV) and analytical performance 
specifications (APS) for the use of cTn in such a manner 
[11]. Currently available BV data for cTnI BV have been sum-
marized by Nordenskjöld et al. [12] and are mostly based 
on [1] analysis with a non-commercial analytical system 
[13], [2] small cohorts of potentially unhealthy individuals 
[12, 14, 15] or [3] based on sampling with a short time inter-
val (24 h) [16]. The scope of our study was to estimate the 
weekly BV of high-sensitive cTnI with two recently released 
commercial methods targeting different epitopes, Siemens 
Atellica and Singulex Clarity (Singulex is as of June 2019 no 
longer on the market), on the well-characterized popula-
tion of the European Biological Variation Study (EuBIVAS) 
[17–20]. The study has been conducted in accordance with 
the European Federation of Clinical Chemistry and Labora-
tory Medicine (EFLM) recommendations [21].
Materials and methods
Individuals
Ninety-one volunteers from five European countries (Italy, Spain, The 
Netherlands, Norway and Turkey) participated in the EuBIVAS. Their 
characteristics are reported in Supplementary Tables 1 and 2, and 
their health status and the exclusion criteria applied are described 
elsewhere in detail [17]. Briefly, 38 men (22–59 years) and 53 women 
(21–69 years), all Caucasians, underwent weekly fasting blood draw-
ings for 10 consecutive weeks (April–June 2015). All the centers fol-
lowed the same preanalytical protocol and used the same blood 
drawing devices and collection tubes (Becton Dickinson, NJ, USA). 
Serum and EDTA plasma samples were aliquoted and sent, frozen in 
dry ice, to the coordinating center San Raffaele Hospital in Milan and 
stored in a freezer at −80 °C until distribution to Clinical laboratory 
of Policlinico of Milan, Italy (EDTA plasma) and to the Department 
of Laboratory Medicine Hospital Universitario La Paz Madrid, Spain 
(serum) for the cTnI analysis (April–July 2018).
The EuBIVAS protocol was approved by the Institutional Ethi-
cal Review board of San Raffaele Hospital in agreement with the 
World Medical Association Declaration of Helsinki and by the Ethical 
Board/Regional Ethics Committee for each center. All participants 
signed a written consent form.
cTnI analysis
Two different analytical systems were applied, with analysis being 
performed in two different centers.
Center 1. Policlinico of Milan. The analyses were performed on 
the Sgx Clarity System (Singulex, Alameda, CA, USA), using EDTA 
plasma as sample material. All samples were measured in duplicate, 
with all samples obtained from the same subject being measured 
using a single reagent pack in a single analytical run. The same sin-
gle reagent lot was used for analysis of samples from all subjects. 
Due to the analytical throughput of the analyzer, a maximum of 
eight subjects per day were measured (160 measurements/day). Sgx 
Clarity cTnI Controls (Singulex, Alameda, CA, USA) were used as 
quality control materials.
Center 2. Hospital Universitario La Paz Madrid. The analyses 
were performed on Siemens Atellica (Siemens Healthineers, Erlan-
gen, Germany), using serum as sample material. All samples were 
measured in duplicate. All samples obtained from the same subject 
were measured using a single reagent pack in a single analytical 
run. All samples were measured for 3 consecutive days (30  sub-
jects, 600 measurements/day) with the same reagent lot. Liquichek 
Cardiac Markers Plus (Bio-Rad, Hercules, CA, USA) was used as 
quality control material.
The technical characteristics of the two analytical methods are 
provided in Supplementary Table 3.
Data analysis
Calculation of the within-subject BV (CVI) estimates was per-
formed using CV-ANOVA, an ANOVA method where data first are 
transformed using the CV transformation [22]. The CV-ANOVA was 
adopted for the analysis as this straightforward, non-parametric 
procedure has been shown to be a robust, largely distribution-free 
procedure for estimating CVA and CVI in three-level nested random 
models [22]. Outlier identification and removal were performed for 
replicates and samples on the CV-transformed data, by assessing 
homogeneity of analytical CV (CVA) (between-replicates) using the 
Bartlett test [23] and homogeneity of CVI using the Cochran test 
[24]. To evaluate differences in concentrations between partici-
pants from the different countries, data were visually inspected 
(data not shown). To examine if there was a general trend in the 
overall concentration over the study period, as described for other 
measurands in the EuBIVAS [19], and if individuals were at steady 
state, we calculated the regression of the mean of the 180 dupli-
cate analysis from every blood drawing 1, 2 …. 10 (pooled mean 
group sample concentrations) versus the blood drawing number 
[1–10]. Subjects were considered in steady state if the 95% con-
fidence intervals (CI) of the slope of the regression line included 
zero. Larger individual systematic changes were identified by the 
homogeneity test of the CVI (Cochran test). The between-subject 
BV (CVG) was estimated by ANOVA on natural log-transformed 
data after applying the Dixon Q test to detect outliers between 
individuals and the Shapiro-Wilk test to verify the normality 
assumption [25].
APS for the analytical imprecision (CVAPS), analytical bias (BAPS), 
RCV and the number of samples needed to reach the homeostatic 
set point were calculated according to the formulas reported in the 
Supplementary Appendix.
Data analyses were performed using Excel 2010 and IBM SPSS 
statistics, version 23.
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Results
The Atellica assay has a higher limit of detection (LoD) 
than Singulex (Supplementary Table 3), with conse-
quences for the number of subjects with measurable 
cTnI concentrations. With the Singulex method, just one 
subject out of 91 had one sample < LoD in both replicates; 
in total 99.4% of samples had measurable concentrations 
(non-reportable results 10 out of 1781 analyses). With the 
Atellica method, only 1286 results out of 1731  measure-
ments (74.3%) were higher than the LoD. So, for the Atel-
lica method, six individuals had no measurable values 
and another 17  had <5  measurable samples. All these 
23 with non-measurable cTnI were excluded from the cal-
culation, 21 of whom were women.
About 6% of the data for each of the two methods 
were eliminated as outliers prior to calculation of CVI 
estimates (see Supplementary Table 4 for details). The 
eliminated samples were the same for both methods, 
except for a few samples due to the different LoD. 
Only two individuals (one man and one woman) had 
samples with concentrations higher than the 99th per-
centile for both methods. The woman (24  years) had 
cTnI concentrations >99th percentile in the last two col-
lected samples when cTnI was measured with the Sin-
gulex assay. Using the Atellica assay, seven out of her 
10  samples were above the 99th percentile for women 
of 38.6 ng/L, varying from 40 to 114 ng/L. The man pre-
sented a cTnI peak in one sample (1380 ng/L for Singulex 
and 7000 ng/L for Atellica) and four other samples just 
above the 99th percentile for men with both methods. 
This study subject was an athlete doing weightlifting 
and the peak sample was taken after strenuous training 
exercise; the creatine kinase in the same sample gave a 
result of 18,500 U/L. Both subjects were excluded from 
the calculations. All the other subjects included in the 
calculation were in steady state. Different numbers of 
individuals were eliminated as outliers based on the 
Dixon test for the two methods prior to the calculation 
of CVG: one woman for Singulex and two women and 
four men for Atellica (see Figures 1 and 2 and Supple-
mentary Table 4). The results of CVA, CVI and CVG esti-
mates obtained for both methods are reported in Table 1. 
When including different number of study subjects as 
basis for the CVI estimates due to the higher LoD for 
Atellica, the CVI estimates obtained with the Singulex 
Clarity and Atellica systems were significantly different 
(i.e. the 95% CI did not overlap) only for the whole study 
population (upper part of Table 1). Results for the male 
subgroups were similar, for the female subgroup slightly 
different, but with overlapping 95% CI. If, however, only 
including the Singulex results from the study subjects 
who were used as basis for the Atellica estimates, the 
Singulex CVI estimates decreased and, even if Atellica 
estimates remained lower, results were no longer statis-
tically different (overlapping 95% CI for all subgroups, 
see Table 1). Mean cTnI values were highly different 
between the two methods, on average about 3 times 
higher for the Atellica system (Table 1). The calculated 
APS and RCVs were similar for the two methods, as was 
Figure 1: cTnI Singulex Clarity.
Range minimum to maximum and median value (hyphen) for each individual ordered by age. The gray bar indicates the median ± CI; 
continuous lines indicate the 5th and 95th percentiles for women and men. The figures report all the individuals whose samples were 
included to derive CVI estimates, and those not included in the calculation of CVG are circled.
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the case also for the index of individuality (II) and the 
number of samples needed to reach the homeostatic 
set point (±10%) (Table 2). Only for men measured on 
Singulex was the II much lower as a consequence of the 
higher CVG.
Discussion
The availability of high-sensitivity cTnI methods with a 
very low LoD and good precision at low cTnI concentra-
tions allows the delivery of CVI estimates in healthy indi-
viduals. This is important because it allows the definition 
of APS based on BV and the definition of RCV based on 
biology. The CVA estimates derived from duplicate analy-
sis of the study samples are higher than the calculated 
CVAPS but it must be taken into consideration that this CVA 
estimate is obtained at a mean cTnI concentration <1 ng/L 
and <3 ng/L for Singulex Clarity and Siemens Atellica, 
respectively, concentrations which are about 10 times 
lower than the respective 99th percentile of the healthy 
population (see Supplementary Table 3). Although sig-
nificant differences were observed between CVI estimates 
based on the two analytical systems for the overall group 
and the female subgroup, this is likely explained by the 
different level of sensitivity of the two analytical methods 
and not by the different epitopes that they recognize. Both 
systems can be categorized as highly sensitive methods 
[3, 26], but for Atellica, in line with the manufacturer’s 
specifications, about 75% of the samples were above the 
LoD and 25% were below (not measurable), while for Sin-
gulex more than 99% were measurable. The individuals 
with non-measurable samples were mostly women (21 out 
53, 40% of females’ results) and only two were men (5.4% 
of the 37 males’ results). Thus, the female study popula-
tion is substantially different for the two methods and this 
explains the different CVI estimates observed between 
women and consequently for the overall estimate. In 
line with this, when the estimates were based on results 
from the same study subjects (second part of Table 1), the 
Singulex estimates decreased, and the difference was no 
longer significantly different. Another possible contribu-
tor to the differences in estimates is the sample materials 
on which the analyses were performed: serum for Atellica 
and EDTA plasma for Singulex.
Our data confirm that women present with lower cTnI 
values, as has been reinforced in several recent papers 
[27–29]. The difference between men and women is more 
evident for Singulex, but as previously detailed, for Atel-
lica 40% of the women had cTnI concentrations below 
the LoD and were thus not included in the calculations. 
It is important to notice the relevant difference in stand-
ardization of the two analytical methods: Siemens Atel-
lica results were on average 3 times greater than Singulex 
Clarity results but for some subjects (seven out of the 
included 66, five women and two men) the difference was 
more than 10 times. This behavior was constant across all 
the 10  samples of these particular subjects, indicating a 
difference in the way the two systems detect and quantify 
the cTnI molecule for these specific subjects. The Singulex 
Figure 2: cTnI Siemens Atellica.
Range minimum to maximum and median value (hyphen) for each individual ordered by age. The gray bar indicates the median ± CI; 
continuous lines indicate the 5th and 95th percentiles for women and men. The figures report all the individuals whose samples were 
included to derive CVI estimates, and those not included in the calculation of CVG are circled.
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Clarity cTnI assay uses a 2 × 2 pair of monoclonal antibod-
ies recognizing epitopes in the central region and at both 
ends of the cTnI molecule; the capture antibodies recog-
nize the amino acid sequences 41–49 and 24–40 and the 
detection antibodies recognize the sequences 190–196 
and 86–90. Siemens Atellica uses two capture monoclonal 
antibodies that recognize epitopes in the C- and N-termi-
nal part of the cTnI molecule and a third detection anti-
body recognizes the N-terminal region of the molecule. 
This different setting of the Atellica method that has the 
capture antibodies at the extreme of the cTnI molecule 
(while Singulex captures the central more stable part of 
the molecule) could be more sensitive to intact cTnI deriv-
ing from recent myocardial damage possibly present in 
subjects with higher cTnI values [30, 31].
These EuBIVAS-derived CVI estimates are in line with 
those published by Wu et al. [13] where a research version 
of the Singulex analytical system was applied and by 
Simpson et  al. [32], but higher than estimates based on 
short-term sampling intervals (within 24 h) [16].
For all but two subjects, all cTnI results were well 
within the 99th percentile for both methods, includ-
ing those subjects who were excluded from the CVG 
calculations.
The CVG estimates obtained with the Atellica system 
(36.5% and 36.3% for men and women, respectively) as 
well as the Singulex CVG for the female group (40.3%) were 
lower than the previously published data. The Singulex 
CVG estimate for men (65.3%) was in line with those pub-
lished by Vasile et al. [33], Wu et al. [13] and van der Linden 
et al. [16] but lower than some other published data. For 
the Singulex method, the only excluded subject from CVG 
calculation was a 47-year-old lady practicing about 17  h 
per week with strenuous physical exercise (running and 
cycling) [30]. This subject was an outlier also for Atellica. 
As evident in Figures 1 and 2, her cTnI results were in the 
range of the male subjects. The lower Atellica-derived 
CVG estimate for men is likely explained by the exclu-
sion of study subjects classified as outliers, who were not 
excluded for Singulex. In fact, with the Atellica method, 
four subjects had significantly higher concentrations than 
the others (see Figure 2) and were excluded according to 
the Dixon algorithm for outlier detection. The same sub-
jects had higher cTnI concentrations when measured by 
the Singulex method than the rest of the group, but not to 
such a high level that they were classified as outliers. This 
may be explained by the different epitope mappings of the 
two analytical systems.
The distribution of the homeostatic points of cTnI 
of the individuals is skewed, and this is reflected by the 
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cautious when applying such estimates for further calcu-
lations, especially APS for bias.
The low II reduces the relevance of reference intervals 
and increases the importance of applying RCV when inter-
preting serial results. The EuBIVAS-derived asymmetrical 
RCVs were similar for the two analytical systems: about 35% 
for decrease and between 50% and 60% for increase. These 
RCVs are thus quite similar to those summarized by Nor-
denskjöld et al. [12] and Simpson et al. [32] and confirm the 
amount of variation expected to be caused by analytical var-
iation and BV when monitoring a patient with cTnI within 
the 99th percentile. Recently, cTnI has been proposed as a 
prognostic marker and its rapid increase (within the 99th 
percentile) may indicate an accelerated myocardial damage 
[10], so knowledge on the natural BV in the long-term setting 
is of importance. Furthermore, in patients undergoing 
therapies with potentially cardiotoxic drugs, the obtained 
data would be highly relevant. Unfortunately, at these low 
 concentration levels, 13–17 samples are needed to identify 
the homeostatic set point ±10%, while 3–4 samples are suf-
ficient to estimate the set point within ±20%.
The limitations of the study are as follows: long 
sample storage before analysis (3 years), but the samples 
were continuously stored at −80 °C and thawed only prior 
to analysis; the study was not targeted to cTn so partici-
pants did not undergo specific cardiological evaluation 
and there is, in particular, a low prevalence of male elderly 
subjects. Furthermore, this study establishes BV estimates 
based on weekly sampling and the obtained results thus 
cannot be directly applied to AMI diagnosis and would 
therefore also not be appropriate to establish APS in an 
emergency context.
Conclusions
This is the first study able to estimate CVI and CVG based 
on weekly samplings applying two different recently 
available high-sensitivity cTnI methods on a large cohort 
of well-characterized healthy individuals, thus deliver-
ing APS and RCV allowing for objectively defined quality 
requirements for analytical methods and for detecting 
likely significant variations when performing serial meas-
urements of cTnI within the 99th percentile.
Acknowledgments: We thank Singulex that allowed us 
to work on a dedicated Singulex Clarity and donated us 
all the necessary reagents and Siemens that donated the 
reagents for the Atellica analyses. We would also like to 
thank all study participants and other EuBIVAS partners 
for their contribution: Gerhard Barla, Bill Bartlett, Giulia 
Cajano, Mario Plebani, Thomas Røraas, Una Ørvim  Sølvik, 
Marit Sverresdotter Sylte, Mustafa Serteser, Francesca 
Tosato and Ibrahim Unsal.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, 
et al. Fourth universal definition of myocardial infarction (2018).  
J Am Coll Cardiol 2018;72:2231–64.
2. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, 
et al. 2015 ESC Guidelines for the management of acute coronary 
syndromes in patients presenting without persistent ST-segment 
elevation. Eur Heart J 2016;37:267–315.
3. Wu AH, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-
Llanos J, et al. Clinical Laboratory Practice Recommendations 
Table 2: Analytical performance specification (APS) for imprecision (CVAPS) and bias (BAPS), reference change values (RCVs), index of 
individuality and number (No.) of samples needed to reach the homeostatic set point based on the biological variation estimates as 
reported in Table 1.
CVAPS (%)a BAPS (%)b RCV (%)cdecrease; 
increase
Index of individuality No. of samples needed to reach 
the homeostatic set point ±10%










APS I GB  0.25 CV  CV
2 2 ;= ( + )  cRCVs were calculated as described in the text delivering asymmetric values for rise and fall 
at the probability level of 95% for significant unidirectional change, applying CVA estimates based on duplicate measurement of all study 
samples.
1746 Ceriotti et al.: Biological variation of cTnI
 for the Use of Cardiac Troponin in Acute Coronary Syndrome: 
Expert Opinion From the Academy of the American Association 
for Clinical Chemistry and the Task Force on Clinical Applica-
tions of Cardiac Bio-Markers of the International Federation 
of Clinical Chemistry and Laboratory Medicine. Clin Chem 
2018;64:645–55.
4. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner 
KJ, et al. Troponin I and cardiovascular risk prediction in the 
general population: the BiomarCaRE consortium. Eur Heart J 
2016;37:2428–37.
5. Body R, Carlton E. Understanding cardiac troponin part 1:  
avoiding troponinitis. Emerg Med J 2018;35:120–5.
6. Fan Y, Jiang M, Gong D, Man C, Chen Y. Cardiac troponin for 
predicting all-cause mortality in patients with acute ischemic 
stroke: a meta-analysis. Biosci Rep 2018;38:BSR20171178.
7. Apple FS, Collinson PO. Analytical characteristics of high-sensi-
tivity cardiac troponin assays. Clin Chem 2012;58:54–61.
8. Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, et al. 
Ultrasensitive flow-based immunoassays using single-molecule 
counting. Clin Chem 2007;53:1990–5.
9. Garcia-Osuna A, Gaze D, Grau-Agramunt M, Morris T, Telha C, 
Bartolome A, et al. Ultrasensitive quantification of cardiac tro-
ponin I by a Single Molecule Counting method: analytical valida-
tion and biological features. Clin Chim Acta 2018;486:224–31.
10. Lyngbakken MN, Røsjø H, Holmen OL, Dalen H, Hveem K, 
Omland T. Temporal changes in cardiac troponin I are associated 
with risk of cardiovascular events in the general population: the 
Nord-Trøndelag Health Study. Clin Chem 2019;65:871–81.
11. Fraser CG, Harris EK. Generation and application of data on 
biological variation in clinical chemistry. Crit Rev Clin Lab Sci 
1989;27:409–37.
12. Nordenskjöld AM, Ahlstrom H, Eggers KM, Frobert O, Jaffe AS, 
Venge P, et al. Short- and long-term individual variation in 
cardiac troponin in patients with stable coronary artery disease. 
Clin Chem 2013;59:401–9.
13. Wu AH, Quynh AL, Todd J, Moecks J, Wians F. Short- and long-
term biological variation in cardiac troponin I measured with 
a high-sensitivity assay: Implications for clinical practice. Clin 
Chem 2009;55:52–8.
14. Scharnhorst V, Krasznai K, van’ t Veer M, Michels RH. Variation 
of cardiac troponin I and T measured with sensitive assays in 
emergency department patients with noncardiac chest pain. Clin 
Chem 2012;58:1208–14.
15. Wu AH, Akhigbe P, Wians F. Long-term biological variation in 
cardiac troponin I. Clin Biochem 2012;45:714–6.
16. van der Linden N, Hilderink JM, Cornelis T, Kimenai DM, Klinken-
berg LJ, van Doorn WP, et al. Twenty-four-hour biological varia-
tion profiles of cardiac troponin I in individuals with or without 
chronic kidney disease. Clin Chem 2017;63:1655–6.
17. Carobene A, Strollo M, Jonker N, Barla G, Bartlett WA, Sandberg 
S, et al. Sample collections from healthy volunteers for biologi-
cal variation estimates’ update: a new project undertaken by the 
Working Group on Biological Variation established by the  
European Federation of Clinical Chemistry and Laboratory  
Medicine. Clin Chem Lab Med 2016;54:1599–608.
18. Carobene A, Røraas T, Sølvik U Ø , Sylte MS, Sandberg S, 
Guerra E, et al. Biological variation estimates obtained from 
91 healthy study participants for 9 enzymes in serum. Clin Chem 
2017;63:1141–50.
19. Aarsand AK, Díaz-Garzón J, Fernandez-Calle P, Guerra E, Locatelli 
M, Bartlett WA, et al. The EuBIVAS: within- and between-subject 
biological variation data for electrolytes, lipids, urea, uric acid, 
total protein, total bilirubin, direct bilirubin, and glucose. Clin 
Chem 2018;64:1380–93.
20. Carobene A, Aarsand AK, Guerra E, Bartlett WA, Coşkun A, Díaz-
Garzón J, et al. European Biological Variation Study (EuBIVAS): 
within- and between-subject biological variation data for 15 
frequently measured proteins. Clin Chem 2019;65:1031–41.
21. Bartlett WA, Braga F, Carobene A, Coşkun A, Prusa R, Fernandez-
Calle P, et al. A checklist for critical appraisal of studies of 
biological variation. Clin Chem Lab Med 2015;53:879–85.
22. Røraas T, Støve B, Petersen PH, Sandberg S. Biological  
variation: the effect of different distributions on estimated 
within-person variation and reference change values. Clin Chem 
2016;62:725–36.
23. Snedecor GW, Cochran WG. Statistical methods, 8th ed. 
Iowa City, IA, USA: Iowa State University Press, 1989.
24. Cochran W. The distribution of the largest of a set of estimated 
variances as a fraction of their total. Ann Eugen 1941;11:47–52.
25. Shapiro S, Wilk M. An analysis of variance test for normality 
(complete samples). Biometrika 1965;52:591.
26. Apple FS. A new season for cardiac troponin assays: it’s time to 
keep a scorecard. Clin Chem 2009;55:1303–6.
27. Kimenai DM, Janssen EB, Eggers KM, Lindahl B, den Ruijter 
HM, Bekers O, et al. Sex-specific versus overall clinical deci-
sion limits for cardiac troponin I and T for the diagnosis of 
acute myocardial infarction: a systematic review. Clin Chem 
2018;64:1034–43.
28. Clerico A, Ripoli A, Masotti S, Musetti V, Aloe R, Dipalo M, et al. 
Evaluation of 99th percentile and reference change values of a 
high-sensitivity cTnI method: a multicenter study. Clin Chim Acta 
2019;493:156–61.
29. Clerico A, Masotti S, Musetti V, Ripoli A, Aloe R, Di Pietro M, 
et al. Evaluation of 99th percentile and reference change values 
of the hs-cTnI method using ADVIA Centaur XPT platform: A 
multicenter study. Clin Chim Acta 2019;495:161–6.
30. Gresslien T, Agewall S. Troponin and exercise. Int J Cardiol 
2016;221:609–21.
31. deFilippi C, Seliger S, Latta F, Peters M, Christenson R,  
Dickfeld T, et al. High-sensitivity cardiac troponin assays  
potentially differentiate acute from chronic myocardial injury. J 
Am Coll Cardiol 2019;73:2904–5.
32. Simpson AJ, Potter JM, Koerbin G, Oakman C, Cullen L,  
Wilkes GJ, et al. Use of observed within-person variation of 
cardiac troponin in emergency department patients for deter-
mination of biological variation and percentage and absolute 
reference change values. Clin Chem 2014;60:848–54.
33. Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS.  
Biologic variation of a novel cardiac troponin I assay. Clin Chem 
2011;57:1080–1.
Supplementary Material: The online version of this article offers 
supplementary material (https://doi.org/10.1515/cclm-2019-1182).
Ceriotti et al.: Biological variation of cTnI 1747
